MERTK and neoplasm: Independent studies have also shown that blocking Mertk on macrophages suppresses efferocytosis and can synergize with anti-PD1 therapeutics, potentially shifting efferocytosis from tumor-associated macrophages into a DC cross-presentation competent compartment (Davra, in press).